• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SELLAS Life Sciences Group, Inc. - Common Stock (NQ:SLS)

10.80 -0.51 (-4.47%)
Delayed Quote Updated: 11:57 AM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,874,826
Open 11.17
Bid (Size) 10.78 (300)
Ask (Size) 10.81 (100)
Prev. Close 11.31
Today's Range 10.71 - 11.27
52wk Range 1.390 - 15.88
Shares Outstanding 15,873,941
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
October 06, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
September 29, 2026
From Pomerantz LLP
Via GlobeNewswire

Performance

52-Week Range 31.9% below 52-week high
10.80
1.3952W Low 15.8852W High
1 Week 11.8% below 1-week high
11.111W Low 12.251W High

SELLAS Life Sciences Group, Inc. - Common Stock (SLS) traded between $1.39 and $15.88 over the past 52 weeks and last traded at $10.80, 31.9% below its 52-week high. Over the past week it ranged between $11.11 and $12.25.

Past 12 Months
-4.6%
-22.6%
-21.5%
+122.3%
+148.4%
+468.7%
1W -$0.53
1M -$3.16
3M -$2.96
6M +$5.94
YTD +$6.46
1Y +$8.90

SLS was +468.7% over the past year, +122.3% over six months, +148.4% year to date, -4.6% in the last week.

12 Months vs Market
SLS
+468.7%
DIA
+9.3%
SPY
+15.7%
QQQ
+24.5%
IWM
+12.7%

Over the past 12 months SLS returned +468.7% versus DIA (Dow) +9.3%, SPY (S&P 500) +15.7%, QQQ (Nasdaq 100) +24.5% and IWM (Russell 2000) +12.7%.

Volume & Liquidity 0.28× 3-mo avg
Today 1,874,826 3-mo avg 6.7M
1W
4.3M
1M
6.1M
3M
6.7M
6M
7.7M
YTD
7.9M
1Y
7.5M

SLS most recently traded 1,874,826 shares against a 3-month average daily volume of 6.7M.

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
September 22, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
September 15, 2026
From Pomerantz LLP
Via GlobeNewswire
SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off? ↗
January 09, 2026
Via Stocktwits
Get insights into the top gainers and losers of Monday's pre-market session. ↗
September 14, 2026
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
September 08, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
September 01, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
SELLAS Stock Hits New Highs: What's Happening Today? ↗
June 26, 2026
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session. ↗
May 13, 2026
Via Chartmill
These stocks are moving in today's after hours session ↗
May 12, 2026
Via Chartmill
News headline image
SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum ↗
March 18, 2026
Via Stocktwits
News headline image
SLS Stock In Spotlight: First AML Patient Enrolled In Phase 2 Leukemia Trial ↗
March 12, 2026
Via Stocktwits
News headline image
SLS Stock Rallies Ahead Of AML Trial Readout — ‘Pharma Bro’ Martin Shkreli Says He’s Still ‘Very Bearish,’ Predicts Drug Will Fail ↗
March 09, 2026
Via Stocktwits
News headline image
Dow, S&P 500, Nasdaq Futures Dip After Wall Street Rebound: Why SLS, ZVRA, RLMD, USO, CASY Are Trending After-Hours ↗
March 09, 2026
Via Stocktwits
Topics ETFs Government Stocks
News headline image
SLS Stock Falls Premarket: CEO Touts GPS Leukemia Strategy, But Investors Stay Cautious As AML Trial Nears Readout ↗
March 09, 2026
Via Stocktwits
News headline image
SLS Stock Takes A Breather After Big Run: Traders Eye AML Summit Featuring Advisor For Clues On Trial Readout ↗
March 06, 2026
Via Stocktwits
News headline image
SLS Stock’s Red-Hot Streak Draws Rising Short Bets — Retail Traders Are Now Betting On A Big Pharma Buyout ↗
March 05, 2026
Via Stocktwits
News headline image
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside ↗
March 04, 2026
Via Stocktwits
News headline image
SLS Stokes Retail Anticipation For Breakout Rally — What’s Driving The Interest? ↗
February 27, 2026
Via Stocktwits
Topics Death
News headline image
Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% ↗
February 23, 2026
Via Stocktwits
Topics Regulatory Compliance
News headline image
SLS Stock In Spotlight On EU Expansion For Cancer Therapy – Retail Says Potential Catalyst For Buyout ↗
January 14, 2026
Via Stocktwits
News headline image
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
January 08, 2026
From Equity Insider
Via GlobeNewswire
Top movers analysis one hour before the close of the markets on 2026-01-06: top gainers and losers in today's session. ↗
January 06, 2026
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
January 06, 2026
Via Chartmill

Frequently Asked Questions

Is SELLAS Life Sciences Group, Inc. - Common Stock publicly traded?
Yes, SELLAS Life Sciences Group, Inc. - Common Stock is publicly traded.
What exchange does SELLAS Life Sciences Group, Inc. - Common Stock trade on?
SELLAS Life Sciences Group, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for SELLAS Life Sciences Group, Inc. - Common Stock?
The ticker symbol for SELLAS Life Sciences Group, Inc. - Common Stock is SLS on the Nasdaq Stock Market
What is the current price of SELLAS Life Sciences Group, Inc. - Common Stock?
The current price of SELLAS Life Sciences Group, Inc. - Common Stock is 10.80
When was SELLAS Life Sciences Group, Inc. - Common Stock last traded?
The last trade of SELLAS Life Sciences Group, Inc. - Common Stock was at 10/08/26 11:57 AM ET
What is the market capitalization of SELLAS Life Sciences Group, Inc. - Common Stock?
The market capitalization of SELLAS Life Sciences Group, Inc. - Common Stock is 171.52M
How many shares of SELLAS Life Sciences Group, Inc. - Common Stock are outstanding?
SELLAS Life Sciences Group, Inc. - Common Stock has 172M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap